Company news

Incyte Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma

November 26, 2019

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting

November 24, 2019

Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

October 28, 2019

Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

October 15, 2019

Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo

October 11, 2019

CORRECTING and REPLACING Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma

September 26, 2019

Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

September 24, 2019

Incyte to Host Investor Conference Call from ESMO 2019

September 22, 2019

Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis

August 22, 2019

Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019

March 31, 2019

← Newer news releases

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 35 decks. Every deck is listed under its year.